Every 10-Q that Ocular Therapeut (OCUL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OCUL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OCUL filings page.
Ocular Therapeutix (OCUL) reported Q3 results marked by heavier R&D spending as it advances AXPAXLI in Phase 3. Revenue was $14.5M versus $15.4M a year ago, while net loss widened to $69.4M from $36.5M. R&D rose to $52.4M (from $37.1M), reflecting increased clinical activity. Year to date, revenue was $38.7M and net loss was $201.3M.
The balance sheet showed cash and cash equivalents $344.8M as of September 30, 2025, plus approximately $445.4M in net proceeds from an underwritten common stock offering that closed on October 1, 2025. The company believes these resources will fund planned expenses and debt service for at least 12 months while observing a $20.0M minimum liquidity covenant under its Barings credit facility.
Q3 operating lines included product revenue of $14.5M, cost of product revenue of $1.8M, selling and marketing of $13.1M, and G&A of $16.0M. Shares outstanding were 213,047,472 as of October 31, 2025; 174,949,558 were outstanding at September 30, 2025.